APA

Sands B. E., Jacobson E. W., Sylwestrowicz T., Younes Z., Dryden G., Fedorak R. & Greenbloom S. (20100930). Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. : Inflammatory bowel diseases.

Chicago

Sands Bruce E, Jacobson Eric W, Sylwestrowicz Thomas, Younes Ziad, Dryden Gerald, Fedorak Richard and Greenbloom Susan. 20100930. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. : Inflammatory bowel diseases.

Harvard

Sands B. E., Jacobson E. W., Sylwestrowicz T., Younes Z., Dryden G., Fedorak R. and Greenbloom S. (20100930). Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. : Inflammatory bowel diseases.

MLA

Sands Bruce E, Jacobson Eric W, Sylwestrowicz Thomas, Younes Ziad, Dryden Gerald, Fedorak Richard and Greenbloom Susan. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. : Inflammatory bowel diseases. 20100930.